MCF7/LCC9: An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross- resistance to the nonsteroidal antiestrogen tamoxifen

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3486-3493

  Brünner, Nils ^a,b   Boysen, Birgitte ^a   Jirus, Stana ^a   Skaar, Todd C ^b   Holst Hansen, Claus ^a   Lippman, Jeremy ^b   Frandsen, Thomas ^a   Spang Thomsen, Mogens ^a   Fuqua, Suzanne A W ^d   Clarke, Robert ^b,c  

^a FINSEN LABORATORY   (Denmark)

^b GEORGETOWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; 4 HYDROXYTAMOXIFEN; ANTIESTROGEN; DRUG VEHICLE; ESTROGEN; FULVESTRANT; PROGESTERONE RECEPTOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; CROSS RESISTANCE; ESTROGEN THERAPY; FEMALE; HORMONE RESPONSE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENETIC MARKERS; HUMANS; MICE; MICE, NUDE; PHENOTYPE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 15644377090     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Trock, B. J., Leonessa, F., and Clarke, R. Multidrug resistance in breast cancer: a meta analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst., 89: 917-931, 1997.
2. Schneider, E., Horton, J. K., Yang, C. H., Nakagawa, M., and Cowan, K. H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 54: 152-158, 1994.
3. Zyad, A., Bernard, J., Tursz, T., Clarke, R., Brockhaus, M., and Chouaib, S. Resistance to TNF-α and Adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression. Cancer Res., 54: 825-831, 1994.
4. Morrow, C. S., Chiu, J., and Cowan, K. H. Posttranscriptional control of glutathione S-transferase pi gene expression in human breast cancer cells. J. Biol. Chem., 267: 10544-10550, 1992.
5. Fuqua, S. A. W., Oesterreich, S., Hilsenbeck, S. G., Von Hoff, D. D., Eckardt, J., and Osborne, C. K. Heat shock proteins and drug resistance. Breast Cancer Res. Treat., 32: 67-71, 1994.
6. Tuccari, G., Rizzo, A., Giuffre, G., and Barresi, G. Immunocytochemical detection of DNA topoisomerase type II in primary breast carcinomas: correlation with clinicopathological features. Virchows Arch. A Pathol. Anat. Hist., 423: 51-55, 1993.
7. Clarke, R., and Brünner, N. Acquired estrogen independence and antiestrogen resistance in breast cancer: estrogen receptor-driven phenotypes? Trends Endocrinol. Metab., 7: 25-35, 1996.
8. Hahnel, R., Twaddle, E., and Ratajczak, T. The influence of synthetic anti-estrogens on the binding of tritiated estradiol-17β by cytosols of human uterus and human breast carcinoma. J. Steroid Biochem., 4: 687-695, 1973.
9. Clarke, R., and Lippman, M. E. Antiestrogen resistance; mechanisms and reversal. In: B. A. Teicher (ed.), Drug Resistance in Oncology, pp. 501-536. New York: Marcel Dekker, Inc., 1992.
10. Nardulli, A. M., Green, G. L., O'Malley, B. W., and Katzenellenbogen, B. S. Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation. Endocrinology, 122: 935-944, 1988.
11. Lam, H-Y. P. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem. Biophys. Res. Commun., 118: 27-32, 1984.
12. Clarke, R., van den Berg, H. W., and Murphy, R. F. Tamoxifen and 17β-estradiol reduce the membrane fluidity of human breast cancer cells. J. Natl. Cancer Inst., 82: 1702-1705, 1990.
13. Ravdin, P. M., Fritz, N. F., Tormey, D. C., and Jordan, V. C. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res., 48: 1026-1029, 1988.
14. Pasqualini, J. R., and Nguyen, B-L. Estrone sulfatase activity and effect of antiestrogens on transformation of estrone sulfate in hormone-dependent vs. independent human breast cancer cell lines. Breast Cancer Res. Treat., 18: 93-98, 1991.
15. Wakeling, A. E., Dukes, M., and Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res., 51: 3867-3873, 1991.
16. Thompson, E. W., Katz, D., Shima, T. B., Wakeling, A. E., Lippman, M. E., and Dickson, R. B. ICI 164,384: a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res., 49: 6929-6934, 1989.
17. Clarke, R., and Brünner, N. Cross resistance and molecular mechanisms in antiestrogen resistance. Endocrine-Related Cancer, 2: 59-72, 1995.
18. Dauvois, S., Danielian, P. S., White, R., and Parker, M. G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. USA, 89: 4037-4041, 1992.
19. Fawell, S. E., White, R., Hoare, S., Sydenham, M., Page, M., and Parker, M. G. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. USA, 87: 6883-6887, 1990.
20. Clarke, R., Brünner, N., Katzenellenbogen, B. S., Thompson, E. W., Norman, M. J., Koppi, C., Paik, S., Lippman, M. E., and Dickson, R. B. Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells. Proc. Natl. Acad. Sci. USA, 86: 3649-3653, 1989.
21. Brünner, N., Boulay, V., Fojo, A., Freter, C., Lippman, M. E., and Clarke, R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res., 53: 283-290, 1993.
22. Clarke, R., Brünner, N., Thompson, E. W., Glanz, P., Katz, D., Dickson, R. B., and Lippman, M. E. The inter-relationships between ovarian-independent growth, antiestrogen resistance and invasiveness in the malignant progression of human breast cancer. J. Endocrinol., 122: 331-340, 1989.
23. Brünner, N., Frandsen, T. L., Holst-Hansen, C., Bei, M., Thompson, E. W., Wakeling, A. E., Lippman, M. E., and Clarke, R. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant which retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res., 53: 3229-3232, 1993.
24. Coopman, P., Garcia, M., Brünner, N., Derocq, D., Clarke, R., and Rochefort, H. Antiproliferative and antiestrogenic effects of ICI 164,384 in 4-OH-Tamoxifen-resistant human breast cancer cells. Int. J. Cancer, 56: 295-300, 1994.
25. Darbre, P., Yates, J., Curtis, S., and King, R. J. B. Effect of estradiol on human breast cancer cells in culture. Cancer Res., 43: 349-354, 1983.
26. Clarke, R., Morwood, J., van den Berg, H. W., Nelson, J., and Murphy, R. F. The effect of cytotoxic drugs on estrogen receptor expression and response to tamoxifen in MCF-7 cells. Cancer Res., 46: 6116-6119, 1986.
27. Munson, P. J., and Rodbard, D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem., 107: 220-239, 1980.
28. Clarke, R., Brünner, N., Katz, D., Glanz, P., Dickson, R. B., Lippman, M. E., and Kern, F. The effects of a constitutive production of TGF-α on the growth of MCF-7 human breast cancer cells in vitro and in vivo. Mol. Endocrinol., 3: 372-380, 1989.
29. Frandsen, T. L., Boysen, B. E., Jirus, S., Spang-Thomsen, M., Dano, K., Thompson, E. W., and Brünner, N. Experimental models for the study of human cancer cell invasion and metastasis. Fibrinolysis, 6 (Suppl. 4): 71-76, 1992.
30. Brünner, N., Bronzert, D., Vindelov, L. L., Rygaard, K., Spang-Thomsen, M., and Lippman, M. E. Effect of growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro in nude mice. Cancer Res., 49: 1515-1520, 1989.
31. Rygaard, K., and Spang-Thomsen, M. "GROWTH": a computer program for determination of mean growth curves and calculation of response to therapy of solid tumor xenografts. In: B. Wu and J. Zheng (eds.), Immune-Deficient Animals in Experimental Medicine, pp. 301-306, Basel: Karger, 1989.
32. Fuqua, S. A. W., Fitzgerald, S. G., Allred, D. C., Elledge, R. M., Nawaz, Z., McDonnel, D., O'Malley, B. W., Greene, G. L., and McGuire, W. L. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res., 52: 483-486, 1992.
33. Greene, G. L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., and Shine, J. Sequence and expression of human estrogen receptor complementary DNA. Science (Washington DC), 231: 1150-1154, 1986.
34. Kumar, V., and Chambon, P. The estrogen receptor hinds tightly to its responsive elements as a ligand-homodimer. Cell, 55: 145-156, 1988.
35. Sanger, F., Nicklen, S., and Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA, 74: 5463-5467, 1977.
36. Seibert, K., Shafie, S. M., Triche, T. J., Whang-Peng, J. J., O'Brien, S. J., Toney, J. H., Huff, K. K., and Lippman, M. E. Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice. Cancer Res., 43: 2223-2239, 1983.
37. van Steenbrugge, G. J., Groen, M., van Kreuningen, A., De Jong, F. H., Gallee, M. W. P., and Schroeder, F. H. Transplantable human prostatic careinoma (PC-82) in athymic nude mice (III): effects of estrogens on the growth of the tumor. Prostate, 12: 157-161, 1988.
38. Brünner, N., Svenstrup, B., Spang-Thompsen, M., Bennet, P., Nielsen, A., and Nielsen, J. J. Serum steroid levels in intact and endocrine ablated Balb/c nude mice and their intact litter mates. J. Steroid Biochem., 25: 429-432, 1986.
39. Soule, H. D., Vasquez, J., Long, A., Albert, S., and Brennan, M. A human cell line from a pleural effusion derived from a human breast carcinoma. J. Natl. Cancer Inst., 51: 1409-1416, 1973.
40. Brünner, N., Boysen, B., Kiilgaard, T. L., Frandsen, T. L., Jirus, S., and Clarke, R. Resistance to 4OH-Tamoxifen does not confer resistance to the steroidal antiestrogen ICI 182,780, while acquired resistance to ICI 182,780 results in cross resistance to 4OH-TAM. Breast Cancer Res. Treat., 27: 135, 1993.
41. Nelson-Rees, W. A., Flandermeyer, R. R., and Hawthorne, P. K. Distinctive banded marker chromosomes of human tumor cell lines. Int. J. Cancer, 16: 74-82, 1975.
42. Whang-Peng, J., Lee, E. C., Kao-Shan, C. S., Seibert, K., and Lippman, M. Cytogenetic studies of human breast cancer lines: MCF-7 and derived variant sublines. J. Natl. Cancer Inst., 71: 687-695, 1983.
43. Gottardis, M. M., Robinson, S. P., and Jordan, V. C. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic nude mice: a model to study the tumoristatic action of tamoxifen. Cancer Res., 48: 812-814, 1988.
44. Osborne, C. K., Coronado, E. B., and Robinson, J. P. Human breast cancer in athymic nude mice: cytostatic effects of long-lerm antiestrogen therapy. Eur. J. Cancer & Clin. Oncol., 23: 1189-1196, 1987.
45. Vogel, C. L., Shemano, L., Schoenfelder, J., Gams, R. A., and Green, M. R. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J. Clin. Oncol., 11: 345-350, 1993.
46. Howell, A., DeFriend, D., Robertson, J. F. R., Blamey, R. W., and Walton, P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, 345: 29-30, 1995.
47. Murphy, L. C., and Dotzlaw, H. Variant estrogen receptor mRNA species in human breast cancer biopsy samples. Mol. Endocrinol., 3: 687-693, 1989.
48. Dotzlaw, H., Alkhalaf, M., and Murphy, L. C. Characterization of estrogen receptor variant mRNAs from human breast cancers. Mol. Endocrinol., 6: 773-785, 1992.
49. Fuqua, S. A. Estrogen receptor mutagenesis and hormone resistance. Cancer (Phila.), 74: 1026-1029, 1994.
50. Muschel, R. J., Williams, J. E., Lowy, D. R., and Liotta, L. A. Harvey ras induction of metastatic potential depends upon oncogene activation and type of recipient cell. Am. J. Pathol., 121: 1-8, 1985.
51. Murphy, L. C., Hilsenbeck, S. G., Dotzlaw, H., and Fuqua, S. A. W. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin. Cancer Res., 1: 155-159, 1995.
52. Jiang, S. Y., Langan-Fahey, S. M., Stella, A. L., McCague, R., and Jordan, V. C. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Mol. Endocrinol., 6: 2167-2174, 1992.
53. Smith, C. L., Nawaz, Z., and O'Malley, B. W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol., 11: 657-666, 1997.
54. Horwitz, K. B. The molecular biology of RU485: is there a role for antiprogestins in the treatment of breast cancer? Endocr. Rev., 13: 146-163, 1992.
55. Van Netten, J. P., Algard, F. T., and Coy, P. Heterogeneous estrogen receptor levels detected via multiple microsamples from individual breast tumors. Cancer (Phila.), 56: 2019-2024, 1985.
56. Van Netten, J. P., Armstrong, J. B., Carlyle, S. S., Goodchild, N. L., Thornton, I. G., Brigden, M. L., Coy, P., and Fletcher, C. Estrogen receptor distribution in the peripheral, intermediate and central regions of breast cancers. Eur. J. Cancer & Clin. Oncol., 24: 1885-1889, 1988.
57. Encarnacion, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M., Fuqua, S. A., and Osborne, C. K. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat., 26: 237-246, 1993.
58. Johnston, S. R. D., Saccanti-Jotti, G., Smith. I. E., Newby, J., and Dowsett, M. Change in oestrogen receptor expression and function in tamoxifen-resistant breast cancer. Endocr. Related Cancer, 2: 105-110, 1995.
59. Goldie, J. H., and Coldman, A. J. A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat. Rep., 63: 1727-1733, 1979.
60. Day, R. S. Treatment sequencing, assymetry. and uncertainty: protocol strategies for combination chemotherapy. Cancer Res., 46: 3876-3885, 1986.
61. Norton, L., and Day, R. Potential innovations in scheduling cancer chemotherapy. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Important Advances in Oncology, pp. 57-73, Philadelphia: J. B. Lippincott Co., 1991.
62. LaBorda, J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal protein PO. Nucleic Acids Res., 19: 3998, 1991.